BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1300 related articles for article (PubMed ID: 12509400)

  • 1. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
    J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia.
    Arbyn M; Buntinx F; Van Ranst M; Paraskevaidis E; Martin-Hirsch P; Dillner J
    J Natl Cancer Inst; 2004 Feb; 96(4):280-93. PubMed ID: 14970277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
    Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
    Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
    J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
    Castle PE; Glass AG; Rush BB; Scott DR; Wentzensen N; Gage JC; Buckland J; Rydzak G; Lorincz AT; Wacholder S
    J Clin Oncol; 2012 Sep; 30(25):3044-50. PubMed ID: 22851570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
    Gage JC; Schiffman M; Katki HA; Castle PE; Fetterman B; Wentzensen N; Poitras NE; Lorey T; Cheung LC; Kinney WK
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25038467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Wait-and-see policy versus loop excision after two consecutive Pap-2 cervical smears: over time less surgery and an equivalent outcome; no substantial contribution to be expected from the detection of high risk human papillomavirus].
    Bekkers RL; Hanselaar AG; Melchers WJ; van Schaik JH; Boonstra H; Massuger LF
    Ned Tijdschr Geneeskd; 2003 Feb; 147(7):302-6. PubMed ID: 12622008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
    Hammer A; Demarco M; Campos N; Befano B; Gravitt PE; Cheung L; Lorey TS; Poitras N; Kinney W; Wentzensen N; Castle PE; Schiffman M
    Int J Cancer; 2020 Sep; 147(6):1612-1620. PubMed ID: 32141607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
    Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV testing with cytology triage for cervical cancer screening in routine practice.
    Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
    Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer.
    Costa S; Sideri M; Syrjänen K; Terzano P; De Nuzzo M; De Simone P; Cristiani P; Finarelli AC; Bovicelli A; Zamparelli A; Bovicelli L
    Acta Cytol; 2000; 44(3):310-8. PubMed ID: 10833984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
    Kjær SK; Frederiksen K; Munk C; Iftner T
    J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.